Haemovigilance for the optimal use of blood products in the hospital

Reesink, H. W.; Panzer, Sarah E.; González, Camilo; Lena, N; Muntaabski, P; Gimbatti, S; Wood, Erica M.; Lambermont, Micheline; Deneys, Véronique; Sondag, D.; Alport, Ted; Towns, Dale; Devine, Dana V.; Turek, Petr; Auvinen, Marja‐Kaisa; Koski, Tyler R.; Lin, Che Kit; Lee, C K; Tsoi, W. C.; Lawlor, Emer; Grazzini, Giuliano; Piccinini, Vanessa; Catalano, Liviana; Pupella, Simonetta; Kato, Hidefumi; Takamoto, Shigeru; Okazaki, Hitoshi; Hamaguchi, Isao; Wiersum‐Osselton, Johanna C.; Tilborgh, Anita J.W. van; Zijlker-Jansen, P.Y.; Mangundap, K M; Schipperus, Martin R.; Dinesh, Dorothy; Flanagan, P; Flesland, Øystein; Steinsvåg, Christine Torsvik; Espinosa, Aurora; Łętowska, Magdalena; Rosiek, Aleksandra; Antoniewicz‐Papis, Jolanta; Lachert, Elżbieta; Koh, Mickey B.C.; Alcantara, Ramir; Alonso, M Corral; Muñiz‐Díaz, Eduardo

doi:10.1111/j.1423-0410.2010.01323.x

Cited by 10 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transfusional Risk Blood transfusions are a medical intervention that presents risks inherent to the procedure and to the biological origin of the component, which is the human being itself [18].…”

Section: Figure 9: Irradiation Of Componentmentioning

confidence: 99%

Transfusion in Oncology

2019

IJCRT

View full text Add to dashboard Cite

show abstract

Section: Figure 9: Irradiation Of Componentmentioning

confidence: 99%

Transfusion in Oncology

2019

IJCRT

View full text Add to dashboard Cite

show abstract

“…This is probably because postransfusional microchimerism in HIV-infected patients is rarely detected, so the universal irradiation of blood components is not recommended. The indications to irradiation are the same as for HIV-negative patients [36,37].…”

Section: Transfusional Riskmentioning

confidence: 99%

Sımple Management of an Acute and Large Wound

2019

JCRC

View full text Add to dashboard Cite

The transfusional support of human immunodeficiency virus-infected patients is a challenge both for the clinical physician and for the blood services, either because of the immunohematological problems or the microbiological/thrombotic risk associated. The immunohematological risk caused by positive crossmatch is resolved by autologous adsorption; if the patient was recently transfused, the adsorption will be homologous. The thrombotic risk (due to hypercoagulable state) is resolved by pretransfusion heparin administration and leukoreduction only in autoimmune hemolytic anemia cases; and the presumed microbiological risk is similar to HIV-negative patients.

show abstract

“…The main challenge is to generate data on the benefit of transfusion of a blood component in different clinical situations in order to be able to make risk-benefit calculations [17]. It is clear that haemovigilance systems and officers may help to collect and analyse the necessary data [18].…”

Section: Futurementioning

confidence: 99%

Haemovigilance: an effective tool for improving transfusion practice

Faber²,

2010

View full text Add to dashboard Cite

Haemovigilance is a tool to improve the quality of the blood transfusion chain, primarily focusing on safety. In this review we discuss the history and present state of this relatively new branch of transfusion medicine as well as some developments that we foresee in the near future. The top 10 results and conclusions are: (1) Haemovigilance systems have shown that blood transfusion is relatively safe compared with the use of medicinal drugs and that at least in Europe blood components have reached a high safety standard. (2) The majority of the serious adverse reactions and events occur in the hospital. (3) The majority of preventable adverse reactions are due to clerical errors. (4) Some adverse reactions such as anaphylactic reactions often are not avoidable and therefore have to be considered as an inherent risk of blood transfusion. (5) Well-functioning haemovigilance systems have not only indicated how safety should be improved, but also documented the success of various measures. (6) The type of organisation of a haemovigilance system is of relative value, and different systems may have the same outcome. (7) International collaboration has been extremely useful. (8) Haemovigilance systems may be used for the vigilance and surveillance of alternatives for allogeneic blood transfusion such as cell savers. (9) Haemovigilance systems and officers may be used to improve the quality of aspects of blood transfusion other than safety, such as appropriate use. (10) Haemovigilance systems will be of benefit also for vigilance and surveillance of the treatment with other human products such as cells, tissues and organs.

show abstract

Haemovigilance for the optimal use of blood products in the hospital

Cited by 10 publications

References 2 publications

Transfusion in Oncology

Transfusion in Oncology

Sımple Management of an Acute and Large Wound

Haemovigilance: an effective tool for improving transfusion practice

Contact Info

Product

Resources

About